Literature DB >> 3260522

A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene.

P Fischer1, E Nacheva, D Y Mason, P D Sherrington, C Hoyle, F G Hayhoe, A Karpas.   

Abstract

We describe the characterization of a new human cell line, Karpas 299 (K299), established from blast cells in the peripheral blood of a 25-year-old white man. His illness, which began with enlarged occipital and axillary nodes and weight loss, ended after 7 months with generalized lymphadenopathy, pleural effusion, and bone marrow involvement. A lymph node biopsy showed a large cell lymphoma mainly sinusoidal in distribution. The blast cells with pleomorphic nuclei resembled primitive histiocytes. The cells, which expressed the T-cell-associated markers CD4 and CD5, were positive for HLA-DR, epithelial membrane antigen, and CD30 (Ki-1 antigen). The karyotype was aneuploid and included a translocation 2;5. The site of translocation on chromosome 5 (at 5q35.1) is in the region of the locus of the c-fms oncogene (receptor of the monocyte-macrophage colony-stimulating factor MCSF or CSF-1). The cell line Karpas 299 has the same karyotype and pattern of antigen expression as the patient's cells. Northern blot analysis of RNA showed an active rearrangement of the T-cell receptor beta-chain gene. This is to our knowledge the first Ki-1 antigen-positive line to be established from a case of non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260522

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

3.  Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Authors:  Bahey Salem; Samantha Miner; Nancy F Hensel; Minoo Battiwalla; Keyvan Keyvanfar; David F Stroncek; Adrian P Gee; Patrick J Hanley; Catherine M Bollard; Sawa Ito; A John Barrett
Journal:  Cytotherapy       Date:  2015-09-28       Impact factor: 5.414

4.  Lymphomas of true histiocytic origin. Expression of different phenotypes in so-called true histiocytic lymphoma and malignant histiocytosis.

Authors:  S M Hsu; Y S Ho; P L Hsu
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

5.  A novel role for IL-22R1 as a driver of inflammation.

Authors:  Ram Savan; Adelle P McFarland; Della A Reynolds; Lionel Feigenbaum; Karthika Ramakrishnan; Megan Karwan; Hidekazu Shirota; Dennis M Klinman; Kieron Dunleavy; Stefania Pittaluga; Stephen K Anderson; Raymond P Donnelly; Wyndham H Wilson; Howard A Young
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

6.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Authors:  Zainul S Hasanali; Elliot M Epner; David J Feith; Thomas P Loughran; Clare E Sample
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

8.  Quantitation in bioluminescence imaging by correction of tissue absorption for experimental oncology.

Authors:  Sabrina Pesnel; Arnaud Pillon; Laurent Créancier; Nicolas Guilbaud; Christian Bailly; Anna Kruczynski; Stéphanie Lerondel; Alain Le Pape
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

9.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.

Authors:  M Grell; G Zimmermann; E Gottfried; C M Chen; U Grünwald; D C Huang; Y H Wu Lee; H Dürkop; H Engelmann; P Scheurich; H Wajant; A Strasser
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

10.  Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.

Authors:  R Krishna Sanka; Ralph C Eagle; Ted H Wojno; Kenneth R Neufeld; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.